as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,805.7
Change
+9.4 (0.52%)
Open
₹1,796.9
Prev. Close
₹1,796.3
Day High
₹1,805.7
Day Low
₹1,778.0
Volume Analysis
Traded
864,937
Delivered
554,001
Delivery %
64.05%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Trading within 3% of its 52-week high (₹1860.0)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (22.4%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,842.64 | ₹1,824.17 | ₹1,814.94 | ₹1,796.47 | ₹1,787.24 | ₹1,768.77 | ₹1,759.54 |
| Fibonacci | ₹1,824.17 | ₹1,813.59 | ₹1,807.05 | ₹1,796.47 | ₹1,785.89 | ₹1,779.35 | ₹1,768.77 |
| Camarilla | ₹1,813.32 | ₹1,810.78 | ₹1,808.24 | ₹1,796.47 | ₹1,803.16 | ₹1,800.62 | ₹1,798.08 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+51.36%
1 Week
-0.08%
1 Month
+14.37%
3 Months
+11.37%
6 Months
+23.38%
1 Year
+49.52%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹964.36
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
9.16%
Net margin 10.8% × asset turnover 0.54x × equity multiplier 1.57x
Company Overview
Sector
Healthcare
Market Cap
₹104,215 Cr
P/E (TTM)
25.7
ROE
10.1%
Book Value
₹685.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Aurobindo Pharma Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Growth (46/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1860.0); strong operating margin (20.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 2.61 times its book value
- −The company has delivered a poor sales growth of 6.32% over past five years.
- −Company has a low return on equity of 10.8% over last 3 years.
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
US FDA classifies Lannett Seymour, Indiana facility OAI after August 17-21, 2026 inspection.
Apitoria Unit 2 received US FDA EIR with VAI classification after September 7-15, 2026 inspection.
Intimation of investors / analysts meet to be held on 17.11.2026.
Intimation of investor / analysts meet to be held on 16.09.2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 | 10,263 |
| Expenses + | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 | 8,110 |
| Operating Profit | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 | 2,153 |
| OPM % | 19.0% | 22.0% | 22.0% | 21.0% | 20.0% | 20.0% | 21.0% | 20.0% | 20.0% | 21.0% | 20.0% | 21.0% | 21.0% |
| Other Income + | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 | 168 |
| Interest | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 | 102 |
| Depreciation | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 | 531 |
| Profit before tax | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 | 1,688 |
| Tax % | 30.0% | 26.0% | 26.0% | 31.0% | 32.0% | 30.0% | 32.0% | 32.0% | 34.0% | 32.0% | 29.0% | 32.0% | 33.0% |
| Net Profit + | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 | 1,124 |
| EPS in Rs | 13 | 16 | 16 | 16 | 14 | 15 | 16 | 14 | 15 | 16 | 16 | 18 | 20 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 26 | 15 | 17 | 10 | 8 | 9 | 11 | 4 | 6 | 8 | 6 | 16 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 36,913 |
| Expenses + | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,164 | 26,783 | 29,357 |
| Operating Profit | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,556 |
| OPM % | 21.0% | 23.0% | 23.0% | 23.0% | 20.0% | 21.0% | 21.0% | 19.0% | 15.0% | 20.0% | 21.0% | 20.0% | 20.0% |
| Other Income + | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 613 | 404 | 632 |
| Interest | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 | 395 |
| Depreciation | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,778 | 1,961 |
| Profit before tax | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,112 | 5,832 |
| Tax % | 28.0% | 26.0% | 25.0% | 25.0% | 24.0% | 24.0% | 27.0% | 22.0% | 26.0% | 28.0% | 31.0% | 31.0% | — |
| Net Profit + | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,987 |
| EPS in Rs | 27 | 35 | 39 | 41 | 40 | 49 | 91 | 45 | 33 | 54 | 60 | 60 | 69 |
| Dividend Payout % | 8.0% | 7.0% | 6.0% | 6.0% | 6.0% | 6.0% | 4.0% | 20.0% | 23.0% | 8.0% | 0.0% | 7.0% | — |
| Sales growth | 50 | 14 | 8 | 10 | 19 | 18 | 7 | -5 | 6 | 17 | 9 | 6 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 | 39,342 |
| Borrowings + | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 8,073 | 8,630 |
| Other Liabilities + | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 12,232 | 13,725 |
| Total Liabilities | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 | 61,754 |
| Fixed Assets + | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,407 | 21,415 |
| CWIP | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 5,214 | 3,487 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 | 354 |
| Other Assets + | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 34,525 | 36,498 |
| Total Assets | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 | 61,754 |
| Equity Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 | 58 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Cash from Investing Activity + | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 | -2,630 |
| Cash from Financing Activity + | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | -1,269 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 | 1,628 |
| Free Cash Flow | 491 | -146 | 1,594 | 714 | 114 | 2,969 | 1,503 | 2,693 | -323 | -1,067 | 1,408 | 2,468 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 67 | 67 | 118 | 70 | 61 | 106 | 87 | 143 | 84 | 72 | 86 | 107 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 6.85% | 6.87% | 6.69% | 6.45% | 6.67% | 6.61% | 6.88% | 6.37% | 6.55% | 7.08% | 6.63% | 6.29% |
| Promoters | 51.84% | 51.84% | 51.8% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.88% | 51.88% |
| Government | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.03% | 0.05% | 0.05% | 0.05% |
| FII | 20.72% | 18.01% | 16.73% | 16.59% | 16.29% | 15.33% | 14.38% | 14.21% | 13.95% | 15.24% | 16.38% | 17.41% |
| DII | 20.6% | 23.28% | 24.77% | 25.14% | 25.21% | 26.23% | 26.93% | 27.6% | 27.66% | 25.82% | 25.05% | 24.37% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Aurobindo Pharma Ltd (this stock) | 104,215 | 25.7 | 2.64 | 10.1% |
| Mankind Pharma Limited | 108,424 | 46.5 | 6.16 | 13.1% |
| Max Healthcare Ins Ltd | 99,557 | 70.1 | 8.82 | 14.7% |
| Cipla Ltd | 112,563 | 36.2 | 3.18 | 11.6% |
| Dr. Reddy S Laboratories | 115,092 | 41.1 | 2.96 | 11.2% |
| Lupin Limited | 89,994 | 16.0 | 3.75 | 28.7% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Aurobindo Pharma Ltd?
Frequently Asked Questions about Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (AUROPHARMA) closed at ₹1,805.7 on NSE on 19 November 2026, up 9.4 (0.52%) from the previous close.
Aurobindo Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol AUROPHARMA.
Aurobindo Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 25.7.
Aurobindo Pharma Ltd has a dividend yield of 0.39%.
Aurobindo Pharma Ltd's 52-week high is ₹1,860.0 and its 52-week low is ₹1,106.0.
Aurobindo Pharma Ltd has a market capitalisation of ₹104,215 crore.
Aurobindo Pharma Ltd has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Aurobindo Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.